BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27825462)

  • 1. Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.
    Pals ST; Kersten MJ; Spaargaren M
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):161-168. PubMed ID: 27825462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
    Jalali S; Ansell SM
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
    de Rooij MF; Kuil A; Kraan W; Kersten MJ; Treon SP; Pals ST; Spaargaren M
    Haematologica; 2016 Mar; 101(3):e111-5. PubMed ID: 26635033
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
    Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
    Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
    Jalali S; Ansell SM
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.
    Ngo HT; Leleu X; Lee J; Jia X; Melhem M; Runnels J; Moreau AS; Burwick N; Azab AK; Roccaro A; Azab F; Sacco A; Farag M; Sackstein R; Ghobrial IM
    Blood; 2008 Jul; 112(1):150-8. PubMed ID: 18448868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of the tissue microenvironment in hairy cell leukemia.
    Sivina M; Burger JA
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):208-16. PubMed ID: 26614899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Waldenström's macroglobulinemia and its individualized therapy options].
    Szemlaky Z; Mikala G
    Orv Hetil; 2017 Oct; 158(41):1604-1614. PubMed ID: 29025291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.
    Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bone marrow niche in Waldenström's macroglobulinemia.
    Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa G; Roccaro A
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):118-20. PubMed ID: 21454209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia].
    Sedlaříková L; Sadílková K; Kubiczková L; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(1):18-23. PubMed ID: 24635433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
    Elsawa SF; Novak AJ; Ziesmer SC; Almada LL; Hodge LS; Grote DM; Witzig TE; Fernandez-Zapico ME; Ansell SM
    Blood; 2011 Nov; 118(20):5540-9. PubMed ID: 21921047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
    Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
    Kapoor P; Ansell SM; Braggio E
    Cancer Treat Res; 2016; 169():321-361. PubMed ID: 27696269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical phenotyping of plasma cells in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia is comparable to flow cytometric techniques.
    Howard MT; Hodnefield J; Morice WG
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):96-8. PubMed ID: 21454202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
    Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
    Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines in the microenvironment of Waldenström's macroglobulinemia.
    Elsawa SF; Ansell SM
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):43-5. PubMed ID: 19362970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Waldenström's macroglobulinemia].
    Watanabe R
    Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.